No Data
Jinkai Biological (301509.SZ) has issued a warning of reduced earnings, expecting an annual net income of 38 million to 45 million yuan, a year-on-year decrease of 74.07%-78.11%.
Jinkai Biotechnology (301509.SZ) disclosed its performance forecast for 2024, and the company expects to belong to the Shareholder...
Jinkai Shengke: 2024 Annual Results Forecast
Jinkai Biological Science (301509.SZ): Core products are applied in the treatment fields of multiple diseases including tumors, cardiovascular and cerebrovascular diseases, diabetes, and kidney diseases.
On January 13, Gelonghui reported that Jinkaishengke (301509.SZ) stated on the investor interaction platform that the company is a small molecule CDMO service provider aimed at Global life science clients, offering customized research, development, and synthesis production services for small molecule drug intermediates and small quantities of Active Pharmaceutical Ingredient for new drug development projects of Global original drug manufacturers. The company's core products are applied in multiple disease treatment areas, including oncology, cardiovascular, diabetes, and kidney diseases.
Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509) Investors Are Less Pessimistic Than Expected
GenScript Biotech Corporation (301509.SZ): Qilu Investment, Blue Zone Fund, and Qingsong Investment plan to collectively reduce their shareholding by no more than 9%.
Glory Union reported on November 26 that Jinkai Biological (301509.SZ) announced that Qilu Investment plans to reduce its shareholding through centralized bidding and block trading by no more than 3,612,000 shares (accounting for 3% of the company's total equity). Blue Area Fund plans to reduce its shareholding through centralized bidding and block trading by no more than 3,612,000 shares (accounting for 3% of the company's total equity). Qingsong Investment plans to reduce its shareholding through centralized bidding and block trading by no more than 3,612,000 shares (accounting for 3% of the company's total equity).
Jinkai Shengke: Report for the third quarter of 2024
